logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Sangamo Therapeutics: Preliminary Data Shows Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients with Fabry Disease

Sangamo Therapeutics Preliminary Results Evaluating Isaralgagene Civaparvovec for Fabry Disease Sangamo Therapeutics ( SGMO ) announced preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920 - a wholly owned gene therapy product candidate, for Fabry disease....

Read More

November 5, 2021

0

Inflation and the Stock Market. ASCO: Different Data's Presentations Promising to Defeat Solid Tumors

Inflation and the Stock Market Inflation, which we were told was but a temporary passing phenomenon, has reached its maximum peak in four decades. We must not get anxious about this inflation, a well-known enemy to the economy and a...

Read More

June 10, 2022

0

Health Canada Approved Amylyx Pharmaceuticals' Product ALBRIOZA for Amyotrophic Lateral Sclerosis

The Great News from Amylyx Pharmaceuticals On Jun. 13, 2022, Amylyx Pharmaceuticals ( AMLX ) announced that Health Canada has approved ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for amyotrophic lateral sclerosis ( ALS ). The important thing to learn...

Read More

June 23, 2022

0

Akero Therapeutics: Two Financing Transactions with Pfizer and Hercules Capital

Akero Therapeutics Financing Transactions Akero Therapeutics ( AKRO ) is one of the selected firms for the Prohost Portfolio . The firm is clinical-stage and develops treatments for metabolic diseases marked by high unmet medical need. The firm’s focus is...

Read More

June 27, 2022

0

PTC Therapeutics' Many Attractive Achievements and Approvals

PTC Therapeutics Approvals and Achievements PTC Therapeutics ( PTCT ) has achieved a lot recently. The latest is the August approval from the U.S. FDA of its product Evrysdi (risdiplam), the first orally administered at-home treatment for spinal muscular atrophy...

Read More

November 18, 2020

0

Regenxbio and AbbVie Inc Agreement. See Also: Gilead Sciences and Everest Medicines News

Regenxbio and AbbVie Inc Agreement Regenxbio ( RGNX ) announced the successful closure of the collaboration and license agreement with AbbVie Inc ( ABBV ) for the development and commercialization of RGX-314, a potential one time gene therapy for wet...

Read More

November 12, 2021

0

Celldex Therapeutics: More Promising Results in Treating Chronic Spontaneous Urticaria Refractory to Antihistamines

Celldex Therapeutics Interim Trial Data for Barzolvolimab Interim data from Celldex Therapeutics ( CLDX ) Phase 1b clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria ( CSU ) refractory to antihistamines demonstrate meaningful symptom improvements....

Read More

July 2, 2022

0

Pfizer and BioNTech Submitted an EUA to the FDA for their COVID-19 Vaccine, BNT162b2

Pfizer, BioNTech & Moderna When asked whether we heard the news about the submission of the Emergency Use Authorization (EUA) and whether we will inform our readers about it. Our answer was that we have posted many articles about Pfizer's...

Read More

November 21, 2020

0

FDA Lifted the Clinical Hold on Vertex Product VX-880 for Type 1 Diabetes

Vertex Pharmaceuticals VX-880 for Type 1 Diabetes Vertex Pharmaceuticals ( VRTX ) announced that the FDA has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880. VX-880 is an investigational allogeneic stem cell-derived, fully differentiated pancreatic...

Read More

July 6, 2022

0

Arcus Biosciences Stock Price Skyrockets Following Gilead Sciences Decision to Augment Their Partnership

Gilead Sciences Collaboration with Arcus Biosciences Sends Stock Through the Roof There is no doubt that Gilead Sciences ( GILD ) is appreciating Arcus Biosciences ( RCUS ) and their collaboration. Both companies announced today that Gilead has exercised its...

Read More

November 18, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 33
  • 34
  • 35
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy